SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001640455-19-000058
Filing Date
2019-06-13
Accepted
2019-06-13 10:32:14
Documents
1
Period of Report
2019-06-12

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_156043631968154.html 4  
1 FORM 4 wf-form4_156043631968154.xml 4 4161
  Complete submission text file 0001640455-19-000058.txt   5515
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37998 | Film No.: 19895107

Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Issuer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences